Aiting Wang

Title: Aiting Wang: Innovator in Tumor Treatment

Introduction

Aiting Wang is a prominent inventor based in Beijing, China. He has made significant contributions to the field of oncology, particularly in the development of treatments for tumors that are unresponsive to immune checkpoint inhibitors.

Latest Patents

Aiting Wang holds a patent for the use of baicalin in the preparation of a drug aimed at treating tumors that are unresponsive to immune checkpoint inhibitors (ICIs) and undergoing hyperprogression. This innovative approach targets excessive Foxp3Treg cells, which contribute to the tumor's resistance to treatment. The patent outlines the use of baicalin in combination with ICIs to effectively inhibit these cells, thereby enhancing the anti-tumor sensitization effect. The targeted tumors include melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), liver cancer, colorectal cancer (CRC), urothelial bladder cancer, and pancreatic cancer.

Career Highlights

Aiting Wang is affiliated with Beijing Friendship Hospital, Capital Medical University, where he continues to advance his research and clinical applications. His work has garnered attention for its potential to improve treatment outcomes for patients with challenging tumor types.

Collaborations

Aiting Wang collaborates with esteemed colleagues, including Dan Yan and Yu Zhang, who contribute to his research efforts and the development of innovative treatment strategies.

Conclusion

Aiting Wang's contributions to cancer treatment through his patent on baicalin exemplify the importance of innovation in addressing complex medical challenges. His work continues to pave the way for advancements in oncology and patient care.